SCD and ovarian carcinoma: Zhang et al. (2019) presented that Ang II treatment increases the formation of multicellular spheroids (MCS), growth and invasiveness of ovarian cancer cell lines by classic direct activation of the MAPK/ERK pathway and transactivation of the epidermal growth factor receptor (EGFR) as well as alleviates ER stress-induced necrosis via modulation of SCD1 levels [12].